Shelton Capital Management’s Corcept Therapeutics CORT Stock Holding History

Shelton Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,379	Closed	-$281K	–	724
2025 Q3	$281K	Hold	3,379	–	–	0.01%	531
2025 Q2	$248K	Sell	3,379 -125,365	-97%	-$9.09M	0.01%	571
2025 Q1	$14.7M	Sell	128,744 -170	-0.1%	-$10.3K	0.35%	69
2024 Q4	$6.5M	Sell	128,914 -10,867	-8%	-$569K	0.16%	136
2024 Q3	$6.47M	Sell	139,781 -713	-0.5%	-$25.3K	0.17%	125
2024 Q2	$4.56M	Buy	+140,494	New	+$3.85M	0.12%	161
2019 Q4	–	Sell	-10,698	Closed	-$151K	–	841
2019 Q3	$151K	Hold	10,698	–	–	0.01%	778
2019 Q2	$119K	Buy	10,698 +10,572	+8,390%	+$118K	0.01%	805
2019 Q1	$10.7K	Sell	126 -10,572	-99%	-$131K	0.04%	380
2018 Q4	$143K	Buy	+10,698	New	+$141K	0.01%	737

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Shelton Capital Management's CORT Position: Q4 2025 in Review

Shelton Capital Management sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 3,379 shares — an estimated $281K sold.

Shelton Capital Management first reported a position in CORT in Q4 2018 and held it in 10 quarters. The position peaked at $14.7M in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

Shelton Capital Management reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
Shelton Capital Management sold 3,379 Corcept Therapeutics shares in Q4 2025, an estimated $281K.
Shelton Capital Management first reported a position in Corcept Therapeutics in Q4 2018 and held it in 10 quarters.
Shelton Capital Management's Corcept Therapeutics position peaked at $14.7M in Q1 2025.
389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Shelton Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.